Therapeutic management of idiopathic pulmonary fibrosis: An evidence-based approach

Clinics in Chest Medicine

Volumn 27, Issue SUPPL., 2006, Pages

  Nathan, Steven D ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIFIBROTIC AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; FG 3019; GAMMA1B INTERFERON; ILOPROST; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PIRFENIDONE; PREDNISONE;

CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DISEASE DURATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EVIDENCE BASED PRACTICE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; MEDICAL SOCIETY; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

ACETYLCYSTEINE; AZATHIOPRINE; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; PIPERAZINES; PREDNISONE; PULMONARY FIBROSIS; PYRIDONES; PYRIMIDINES; RECEPTORS, TUMOR NECROSIS FACTOR; SULFONAMIDES;

EID: 33644976115     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2005.08.004     Document Type: Review

References (56)

1. T.E. King Jr, U. Costabel, and J.-F. Cordieer Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement Am J Respir Crit Care Med 161 2000 646 664
2. L. Richeldi, H.R. Davies, and G. Ferrara Corticosteroids for idiopathic pulmonary fibrosis The Cochrane Library, Issue 1 2004 John Wiley & Sons, Ltd Chichester (UK)
3. H.R. Davies, L. Richeldi, and E.H. Walters Immunomodulatory agents for idiopathic pulmonary fibrosis The Cochrane Library, Issue 1 2004 John Wiley & Sons, Ltd Chichester (UK)
4. P.W. Noble, and R.J. Homer Idiopathic pulmonary fibrosis: new insights into pathogenesis Clin Chest Med 25 4 2004 749 758
5. M. Selman, V.J. Thannickal, and A. Pardo Idiopathic pulmonary fibrosis. Pathogenesis and therapeutic approaches Drugs 64 4 2004 405 430
6. A.S. Narayanan, J. Whithey, and A. Souza Effect of γ-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts Chest 101 5 1992 1326 1331
7. J.G. Clark, T.F. Dedon, and E.A. Wayner Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts J Clin Invest 83 5 1989 1505 1511
8. O. Eickelberg, A. Pansky, and E. Koehler Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts FASEB J 15 3 2001 797 806
9. S.D. Oldroyd, G.L. Thomas, and G. Gabbiani Interferon-gamma inhibits experimental renal fibrosis Kidney Int 56 6 1999 2116 2127
10. A. Billiau, H. Heremans, and K. Vermeire Immunomodulatory properties of interferon-gamma. An update Ann NY Acad Sci 856 1998 22 32
11. W.C. Liles Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases Semin Respir Infect 16 1 2001 11 17
12. G. Gurujeyalakshmi, and S.N. Giri Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression Exp Lung Res 21 5 1995 791 808
13. R.K. Coker, and G.J. Laurent Pulmonary fibrosis: cytokines in the balance Eur Respir J 11 6 1998 1218 1221
14. M.D. Burdick, L.A. Murray, and M.P. Keane CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling Am J Respir Crit Care Med 171 2005 261 268
15. R. Ziesche, E. Hofbauer, and K. Wittmann A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis N Engl J Med 341 17 1999 1264 1269
16. G. Raghu, K.K. Brown, and W.Z. Bradford A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N Engl J Med 350 2 2004 125 133
17. T.E. King Jr, S. Safrin, and K.M. Starko Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis Chest 127 1 2005 171 177
18. R.M. Strieter, K.M. Starko, and R.I. Enelow Idiopathic Pulmonary Fibrosis Biomarkers Study Group. Effects of interferon-γ 1b on biomarker expression in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 170 2004 133 140
19. E.K. Bajwa, N.T. Ayas, and M. Schulzer Interferon gamma-1b therapy in IPF: a meta-analysis Chest 128 2005 203 206
20. InterMune, Inc. INSPIRE: international study of survival outcomes in idiopathic pulmonary fibrosis (IPF) with interferon gamma-1b (IFN-g 1b) Available at: http://inspiretrial.com/wt/page/index Accessed April 13, 2005
21. ClinicalTrials.gov. The INSPIRE trial: a study of interferon gamma-1b for idiopathic pulmonary fibrosis (IPF). Available at: http://www.clinicaltrials. gov/ct/gui/show/NCT00075998. Accessed April 13, 2005
22. A.M. Cantin, S.L. North, and G.A. Fells Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis J Clin Invest 79 6 1987 1665 1673
23. J. Behr, K. Maier, and F. Krombach Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis Am Rev Respir Dis 144 1 1991 146 150
24. A.M. Cantin, R.C. Hubbard, and R.G. Crystal Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis Am Rev Respir Dis 139 2 1989 370 372
25. A. Gillissen, and D. Nowak Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy Respir Med 92 4 1998 609 623
26. J. Behr, K. Maier, and B. Degenkolb Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am J Respir Crit Care Med 156 6 1997 1897 1901
27. M. Demedts, J. Behr, and R. Buhl High-dose acetylcysteine in idiopathic pulmonary fibrosis N Engl J Med 353 21 2005 2229 2242
28. K.A. Fagan, I.F. McMurtry, and D.M. Rodman Role of endothelin-1 in lung disease Respir Res 2 2 2001 90 101
29. G. Sun, M.A. Stacey, and A. Bellini Endothelin-1 induces bronchial myofibroblast differentiation Peptides 18 9 1997 1449 1451
30. B. Hocher, A. Schwarz, and K.A. Fagan Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice Am J Respir Cell Mol Biol 23 1 2000 19 26
31. S.-H. Park, D. Saleh, and A. Giaid Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist Am J Respir Crit Care Med 156 1997 600 608
32. S.E. Mutsaers, R.P. Marshall, and N.R. Goldsack Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats Pulm Pharmacol Ther 11 2-3 1998 221 225
33. ClinicalTrials.gov. Efficacy and safety of oral bosentan in patients with idiopathic pulmonary fibrosis. Available at: http://www.clinicaltrials.gov. Accessed March 15, 2005
34. S.N. Iyer, G. Gurujeyalakshmi, and S.N. Giri Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J Pharmacol Exp Ther 291 1 1999 367 373
35. S.N. Iyer, D.M. Hyde, and S.N. Giri Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation Inflammation 24 5 2000 477 491
36. G. Raghu, W.C. Johnson, and D. Lockhart Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Results of a prospective, open-label phase II study Am J Respir Crit Care Med 159 1999 1061 1069
37. S. Nagai, K. Hamada, and M. Shigematsu Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis Intern Med 41 12 2002 1118 1123
38. A. Azuma, T. Nukiwa, and E. Tsuboi Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Online Am J Respir Crit Care Med [serial online] January 21, 2005
39. Y. Miyazaki, K. Araki, and C. Vesin Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis J Clin Invest 96 1 1995 250 259
40. M. Fujita, J.M. Shannon, and O. Morikawa Overexpression of tumor necrosis factor-α diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-β Am J Respir Cell Mol Biol 29 6 2003 669 676
41. M. Whyte, R. Hubbard, and R. Meliconi Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms Am J Respir Crit Care Med 162 2 2000 755 758
42. A. Niden, M. Koss, and C.T. Boylen An open label pilot study to determine the potential efficacy of TNFR:FC (Enbrel®, etanercept) in the treatment of usual interstitial pneumonia (UIP) [abstract] Am J Respir Crit Care Med 165 2002 D27
43. ClinicalTrials.gov. Idiopathic pulmonary fibrosis: etanercept. Available at: http://www.clinicaltrials.gov. Accessed April 14, 2005
44. The Coalition for Pulmonary Fibrosis IPF research Available at: http://www.coalitionforpf.org/IPFResearch/default.asp Accessed March 15, 2005
45. C. Beham-Schmid, U. Apfelbeck, and H. Sill Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis Blood 99 1 2002 381 383
46. A. Abdollahi, M. Li, and G. Ping Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J Exp Med 201 6 2005 925 935
47. Y. Aono, Y. Nishioka, and M. Inayama Imatinib as a novel anti-fibrotic agent in bleomycin-induced pulmonary fibrosis in mice Online Am J Respir Crit Care Med [serial online] February 25, 2005
48. C.E. Daniels, M.C. Wilkes, and M. Edens Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis J Clin Invest 114 9 2004 1308 1316
49. Division of Pulmonary and Critical Care at the University of Miami, School of Medicine/Jackson Memorial Medical Center. Listing of ongoing clinical trials-Gleevec Available at: http://www.med.Miami.edu/med/IPF/index.asp#Gleevec Accessed April 14, 2004
50. D.A. Zisman, J.P. Lynch III, and R.M. Strieter Pulmonary arterial hypertension (PAH) is common in patients with idiopathic pulmonary fibrosis referred for lung transplantation Am J Respir Crit Care Med 2 2005 A123
51. J. Gagermeier, J. Dauber, and K. Gibson Prevalence of secondary pulmonary hypertension in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2 2005 A205
52. H.F. Nadrous, P.A. Pellikka, and M.J. Krowka Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Chest 128 4 2005 2393 2399
53. H. Olschewski, H.A. Ghofrani, and D. Walmrath Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis Am J Respir Crit Care Med 160 1999 600 607
54. H.A. Ghofrani, R. Wiedemann, and F. Rose Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial Lancet 360 2002 895 900
55. L.H. Pan, K. Yamauchi, and M. Uzuki Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF Eur Respir J 17 6 2001 1220 1227
56. Y. Mageto, K. Flaherty, and K. Brown Safety and tolerability of human monoclonal antibody FG-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis [abstract] Chest 126 4 Suppl 2004 S773